Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.

@article{Seck2010SafetyAE,
  title={Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.},
  author={Thomas L Seck and Michael A Nauck and Dade Sheng and S Sunga and Melanie J. Davies and Peter P. Stein and Keith L. Kaufman and John M. Amatruda},
  journal={International journal of clinical practice},
  year={2010},
  volume={64 5},
  pages={
          562-76
        }
}
OBJECTIVES To evaluate the 2-year safety and efficacy of adding sitagliptin or glipizide to ongoing metformin in patients with type 2 diabetes. METHODS Patients who were on a stable dose of metformin (> or = 1500 mg/day) for at least 8 weeks were randomised in a double-blind manner to receive either sitagliptin 100 mg q.d. (N = 588) or glipizide 5 mg/day (up-titrated up to 20 mg/day based upon prespecified glycaemic criteria) (N = 584). The efficacy analysis assessed the change in HbA(1c… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 108 CITATIONS, ESTIMATED 39% COVERAGE

Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.

  • Expert opinion on drug safety
  • 2015
VIEW 11 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

Sitagliptin/Metformin Fixed-Dose Combination

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

  • Diabetes technology & therapeutics
  • 2012
VIEW 3 EXCERPTS
CITES RESULTS & METHODS
HIGHLY INFLUENCED

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 9 Citations per year from 2017 through 2019